Professor Carl-Henrik Heldin strengthens the Board of Kancera


Kancera announces that Professor Carl-Henrik Heldin has been elected to Kancera´s Board at the company’s annual general meeting May 28.

Professor Heldin is since 1986 director of the Ludwig Institute for Cancer Research in Uppsala, and since 1992 professor of molecular cell biology at Uppsala University. He has a solid reputation and extensive network from assignments as advisor to several academic institutions including the German Cancer Research Center, Heidelberg, the European Institute of Oncology, Milan, the European Molecular Biology Laboratory, Heidelberg and the Max Planck Institute in Martinsried. Professor Heldin is also Vice President of the European Research Council. He has over 380 published scientific articles and 190 reviews and has been awarded prestigious research prizes in Sweden, France and the U.S. Professor Heldin is advisor to the biotech companies Kolltan Pharmaceuticals (USA) and MolMed SpA (Italy).

“We are very pleased to welcome Carl-Henrik Heldin to Kancera. He brings a large international network within cancer research and among successful biotech entrepreneurs. He also provides an international view on how Kancera´s projects are valued scientifically and industrially, “said Thomas Olin, CEO.

Heldin comments: “I now look forward to contributing actively in the Board of Kancera. The company’s projects are exciting and of high quality. They open new and important opportunities to combat cancers which today are difficult to treat. The experience and technical resources that I see in Kancera provide an excellent opportunity for a successful development of the project portfolio.”

Kanceras board consists of:
Erik Nerpin (Chairman), Prof. Hakan Mellstedt (Member), Bernt Magnusson (Member), Prof. Carl-Henrik Heldin (Member) and Thomas Olin (CEO).

About Kancera AB (publ)
Kancera is engaged in drug development that takes its start in new treatment concepts and ends with a candidate drug. Kancera is currently developing medicines for the treatment of both leukemia and solid tumors that interferes with survival signaling and nutrient metabolism within the cancer cell. Kancera is also developing stem cell-based cancer models to study the candidate molecules before testing in humans. Kancera operates in Stockholm and employs approximately 20 people. The share is traded on the NASDAQ OMX First North and the number of shareholders is about 1500. Remium AB is Certified Adviser to Kancera.

For additional information, please contact:
Thomas Olin, CEO: Tel +46 735 20 40 01

Kancera AB (publ)
Karolinska Institutet Science Park
Banvaktsvägen 22
SE 171 48 Solna

Please visit the company’s web